YORK, Pa., March 21, 2011 /PRNewswire/ — Unilife Corporation
(“Unilife” or the “Company”) (Nasdaq:
UNIS; ASX: UNS) today announced that its Chief Operating
Officer and Executive Vice President, Dr. Ramin Mojdeh, has made an
open market purchase of Company shares.
Dr. Mojdeh purchased a total of 54,000 shares of Unilife’s
common stock at an average price of $4.61 per share, with an
approximate value of $248,652. This open market purchase by Dr.
Mojdeh follows similar activity undertaken by Unilife CEO Alan
Shortall, as reported on March 16, 2011.
Dr. Mojdeh stated, “Since joining Unilife just six weeks ago, I
have grown increasingly impressed by the Company’s proprietary
technologies, operational capabilities and commercial position.
With initial production of the Unifill syringe about to
commence, we are now entering an important period of business
development. As we remain on schedule to fill our initial
orders for the Unifill syringe starting in June 2011, and are
continuing to accelerate discussions with a number of interested
pharmaceutical companies, I have decided to make an open market
purchase of Unilife shares at this time.”
Dr. Mojdeh has more than 25 years of business leadership
experience across multiple industries, including 18 years in the
design, development, manufacturing, sales and marketing of
therapeutic and diagnostic medical devices for several
multinational companies including Becton Dickinson (BD), GE
Healthcare and Guidant. Prior to joining Unilife in February 2011,
he served as Vice President and General Manager of BD
Pharmaceutical Systems, North America between 2008 and 2010 and
Worldwide Vice President of Research and Development, BD Medical
between 2002 and 2008.
About Unilife CorporationUnilife Corporation is a U.S.-based
medical device company focused on the design, development,
manufacture and suppl
‘/>”/>
SOURCE
